Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Salivation inhibition fails to reduce radioiodine toxicity in prostate cancer

Key clinical point: Use of intravenous glycopyrronium bromide had no significant impact on radiation toxicity in prostate cancer patients treated with the prostate-specific membrane antigen 177Lu/225Ac-PSMA.

Major finding: The average PSMA uptake in the parotid glands in the intervention group vs. control were 5.72 and 5.57; average PSMA uptake in the submandibular glands for the two groups was 5.89 and 6.25, respectively.

Study details: The data come from 10 prostate cancer patients who underwent PET scans with and without intravenous injections of 0.2 mg glycopyrronium bromide (GPB) to potentially reduce the impact of radiation on the salivary glands.

Disclosures: The study was supported by the Dutch Cancer Society KWF. The researchers had no financial conflicts to disclose.


Mohan V et al. EJNMMI Res. 2021 Mar 12. doi: 10.1186/s13550-021-00770-1.